公开(公告)号：TR9801532T2

公开(公告)日：1998-11-23

申请号：TR9801532

申请日：1997-02-10

Applicant: BASF AG

Inventor： SALFELD JACHEN G ,  ALLEN DEBORAH J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MACGUINESS BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  HOOGENBOOM HENDRICUS R J M ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68

CPC classification number: C07K16/241 ,  A61K38/00 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  Y02A50/412 ,  Y10S424/81

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor alpha(hTNFalpha) are disclosed. These antibodies have high affinity for hTNFalpha (e.g., Kd=10-8 M or less), a slow off rate for hTNFalpha dissociation (e.g., Koff=10-3sec-1 or less) and neutralize hTNFalpha activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFalpha and for inhibiting hTNFalpha activity, e.g., in a human subject suffering from a disorder in which hTNFalpha activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：TR199801532T2

公开(公告)日：1998-11-23

申请号：TR9801532

申请日：1997-02-10

Applicant: BASF AG

Inventor： SALFELD JACHEN G ,  ALLEN DEBORAH J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MACGUINESS BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  HOOGENBOOM HENDRICUS R J M ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., Kd=10−8 M or less), a slow off rate for hTNFα dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNFα and for inhibiting hTNFα activity, e.g., in a human subject suffering from a disorder in which hTNFα activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.